Durham, North Carolina Thursday, April 17, 2025, 12:00 Hrs [IST] ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that the U.S. Food and Drug ...

Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel ...

A new study shows that gold nanoparticles injected into the retina can restore vision in mice with retinal degeneration, offering a less invasive alternative to current retinal prostheses.

DURHAM, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent ...

Home monitoring of neovascular age-related macular degeneration, an interesting concept with many potential benefits, has ...

The study is still recruiting patients older than six years to receive a one-time subretinal injection of ATSN-201 in one eye. The second part of the trial will include pediatric participants as ...

The first pediatric participant, aged 16 (at time of consent), received a single subretinal injection of OPGx-LCA5 and clinically meaningful improvement in vision was observed at one-month post ...